Omega Laboratories Delivers Marijuana Breath Test Validation Packet to Cannabix Technologies Inc. - Completing Major Milestone under Strategic Partnership
This validation included a test method for the simultaneous quantification of Δ-9-tetrahydrocannabinol (THC), Δ-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols collected using Cannabix Technologies' Breath Collection Unit (BCU) and Breath Cartridges (BC). The delivery of the Validation Packet completes a major milestone under the strategic partnership and development agreement ('SPDA') between Cannabix and Omega. This establishes Omega and Cannabix as the premier technology for collecting and testing breath for recent marijuana usage. Cannabix's MBT is a lab-based, collect and send solution, focused on 'recent use' detection of delta-9 THC as opposed to urine, blood and saliva methods (that can detect delta-9 THC many hours, days, or even weeks after consumption). (1)
Omega Laboratories is an international industry leader in forensic drugs of abuse testing for over twenty years. Omega has multiple federal as well as international certifications and accreditations for its world class facility and has extensive experience in novel technology for detection of drugs of abuse.
Cannabix and Omega are moving quickly to launch with select key clients and ramping up commercialization efforts for the Marijuana Breath Test. Omega Laboratories is currently integrating breath testing using Cannabix Breath Cartridges into its suite of services and testing protocols. Among various initiatives underway the Company and Omega are working together on marketing, distribution, support, manufacturing and logistics for the MBT.Figure 1. Cannabix Marijuana Breath Test (BCU and Breath Cartridge)
Under the SPDA, in consideration for the completion and delivery of the Validation Packet by Omega, the Company will convert 3 million Special Warrants into Special Warrant Shares to Omega. Furthermore, Omega will have the right to appoint one person to the board of directors of the Company in due course.
(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104.
About Omega Laboratories, Inc.
Omega Laboratories, headquartered in Mogadore, Ohio with an additional state-of-the-art facility in Ontario, Canada provides laboratory-based advanced testing solutions to over 6,000 clients worldwide. Omega Laboratories has over 24 years of experience in pioneering innovative drug testing methodologies, specializing in the detection of drugs of abuse utilizing Hair, Oral Fluid, Urine and Breath specimens. Omega continues to innovate with the launch of their Technical Solutions portfolio that incorporates a paperless Custody & Control Form system (oCCF) in fourteen languages, licensure of a Laboratory Information Management System (LIMS) designed specifically for Toxicology and powers new laboratories in countries that have demand for local service providers.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring
We seek Safe Harbor.
On behalf of the Board of Directors
'Rav Mlait'
CEOCannabix Technologies Inc.
For further information, contact the Company at
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking StatementsThis news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the CSE may not approve the issuance of the securities; that the Company's development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any 'patent pending' or 'provisional patents' technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5cf449ae-9547-4a9f-9911-30ea2c012243Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Thoma Bravo Is Said to Be in Talks to Buy Software Firm Dayforce
(Bloomberg) -- Thoma Bravo is in talks to acquire human resources management software provider Dayforce Inc., according to people familiar with the matter. The buyout firm is planning to take the Minneapolis-based company private in a deal that could be announced as soon as the coming weeks, the people said, asking not to be identified as the matter is private. The US-Canadian Road Safety Gap Is Getting Wider A Photographer's Pipe Dream: Capturing New York's Vast Water System Festivals and Parades Are Canceled Amid US Immigration Anxiety A London Apartment Tower With Echoes of Victorian Rail and Ancient Rome Princeton Plans New Budget Cuts as Pressure From Trump Builds Shares of Dayforce rose as much as 22% in pre-market New York trading on Monday. The company, whose shares also trade on the Toronto Stock Exchange, had a market value of about $8.4 billion at the close on Friday. While discussions are advanced, they could still be delayed or falter and it's possible another bidder may emerge, the people said. Representatives for Thoma Bravo and Dayforce didn't immediately respond to requests for comment. Dayforce shares have fallen about 60% from their 2021 peak through Friday. While the company increased revenue more than 70% between 2021 and 2024 and became more profitable, the enterprise software market has had difficulties maintaining momentum after a runup during Covid-19 lockdowns. Companies spent money at the time to upgrade their systems, only to pull back after offices reopened in a shaky economy. 'We would not be surprised if DAY chose to sell given the lack of appreciation for the stock in the public markets,' Jefferies Financial Group Inc. analysts including Samad Samana wrote in a note to clients after the Bloomberg report. 'It has been tough sledding for DAY the last few years post-Covid highs, not unlike the rest of the HR/payroll coverage universe. However, it has also underperformed the entire group.' Thoma Bravo, led by co-founder Orlando Bravo, has remained an active buyer this year in what has remained a challenging environment for private equity firms seeking to deploy capital. It agreed to purchase Boeing Co.'s flight navigation unit and other digital assets for $10.6 billion in April, and in July it struck a $2 billion deal to buy restaurant software maker Olo Inc. The firm has been in talks about a potential takeover of Verint Systems Inc., Bloomberg News reported last month. Dayforce, which rebranded from Ceridian HCM Holding Inc. last year, provides AI-powered software for managing recruitment, payrolls and employee career development. Its customers include companies in the health-care, retail and hospitality and financial services sectors. With about $1.2 billion in debt, the company has an enterprise value of more than $9 billion, according to data compiled by Bloomberg. --With assistance from Amy Thomson. (Updates with pre-market trading, industry context from third paragraph.) What Declining Cardboard Box Sales Tell Us About the US Economy Americans Are Getting Priced Out of Homeownership at Record Rates Living With 12 Strangers to Ease a Housing Crunch Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan How Syrian Immigrants Are Boosting Germany's Economy ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
Free Genetic Tests May Aid People With Rare Kidney Disease
Genetic testing covered by companies that make treatments for primary hyperoxaluria can help identify cases of this rare condition, which often leads to kidney failure at an early age. Alnylam Pharmaceuticals, Inc., maker of the lumasiran (Oxlumo), partnered with Prevention Genetics, a unit of Exact Sciences Corporation, to run a testing program free of charge for individuals in the US and Canada. Novo Nordisk, maker of nedosiran (Rivfloza), works with Blueprint Genetics on a similar program. These programs make it easier for physicians treating patients whose medical histories raise concerns about possible primary hyperoxaluria, said Matthew Breeggemann, MD, a nephrologist and co-medical director of the UCSF's Kidney Stone Prevention Clinic. The test kits are mailed to patients. 'The patient just swabs the inside of their cheek and then mails it back. And you can get results sometimes within 2, 3 weeks,' he told Medscape Medical News . Physicians are not required to prescribe the company's primary hyperoxaluria drug when their patients are tested through its sponsored program, Breeggemann said. 'We take advantage of [these programs] to help our patients like we should, but it doesn't mean you need to use that company's drug — the ultimate choice is up to the patient and what is covered by their health insurance plan,' he said. Excess Oxalate Primary hyperoxaluria type 1, the most common form, has been estimated to affect about 1 to 3 per 1 million people, but some research suggests it may be more common. In primary hyperoxaluria, the liver can't properly regulate the production of oxalate. So the kidneys wind up with excess oxalate, which can combine with calcium to form kidney stones. Over time, oxalate builds up in the body, leading to complications including arrhythmias and cardiac arrest, gangrene, and bone and joint pain and fractures. One of the potential clues for primary hyperoxaluria is finding kidney stones in children because this is unusual, Breeggemann said. In adults, one signal of this condition would be a finding of high urine oxalate levels on a lab test, Breeggemann noted. Other signs include frequent formation of kidney stones or having family members with a history of kidney stones. Physicians may also consider genetic testing for primary hyperoxaluria in patients who have kidney stones and unexplained chronic kidney disease, especially in those who don't have hypertension or diabetes, Breeggemann said. Limited but Growing Treatment Options For many years, treatments for primary hyperoxaluria were limited. Patients could try to maintain high fluid intake — intended to maintain brisk flow of diluted urine — and take citrate supplements — intended to increase urinary oxalate solubility. Vitamin B6 may also be prescribed. Some patients would have liver transplants in attempts to address the root cause of their illness. Some would undergo combined or sequential liver and kidney transplants, often preceded by periods of intensive dialysis. This sometimes involved hemodialysis many days of the week and peritoneal dialysis nightly. But there's been a marked change recently in the landscape of treatments for primary hyperoxaluria. Alnylam said lumasiran was the first approved pharmaceutical therapy for this condition. US and EU regulators cleared it in 2020. Lumasiran is a small interfering RNA (siRNA) designed to inhibit the production of oxalate. In 2023, Novo Nordisk received US approval of its siRNA drug, nedosiran, also designed to curb oxalate production. Several companies have investigational agents in clinical development for the treatment of primary hyperoxaluria as well, Alnylam noted in a regulatory filing. These include Biocodex, Inc., and YolTech Therapeutics. In addition, Arbor Biotechnologies is working on a drug candidate, ABO-101, that it describes as 'a novel gene editing therapeutic' designed to address primary hyperoxaluria type 1. Breeggemann reported receiving consulting fees from Novo Nordisk and Alnylam Pharmaceuticals.
Yahoo
an hour ago
- Yahoo
Ottawa-imposed 'airport rent' is driving up cost of plane tickets, think tank finds
OTTAWA — A leading free-market think tank is calling on Ottawa to stop playing landlord to major airports, arguing that exorbitant land rental fees are driving up the cost of domestic air travel. 'Using airports as cash cows instead of treating them as critical infrastructure hurts families, workers, and patients who depend on reliable air service for treatment access,' says Samantha Dagres, the communications manager at the Montreal Economic Institute (MEI). Canada's airports are operated by private, non-profit organizations, known as airport authorities, but the land they sit on is owned by the federal government, which collects rent. Airports forked over a record $494.8 million in rental fees to Ottawa last year, with the 'Big Three' — Toronto Pearson, Montreal-Trudeau and Vancouver International — footing most of the bill. This was a 68 per cent increase from 2014. Each airport's rental fee is calculated based on its gross revenue, topping out at 12 per cent. These costs are passed down to air travellers, making up as much as a third of the airport improvement fee tacked onto the price of their ticket. The average airport improvement fee charged on a Canadian domestic flight is $38, according to Westjet. This is twice the corresponding Australian fee and four times more than what U.S. air travellers pay on their tickets. Canadian air travellers also pay higher airport security charges and, indirectly, aviation fuel excise taxes than their Australian and U.S. peers. All told, MEI found that government-imposed taxes, fees and rent charges made up as much as 43 per cent of ticket prices along major domestic routes. 'Reducing the cost of air travel is entirely within Ottawa's control, because it is Ottawa that is driving prices up in the first place,' said Dagres. Dagres and her colleagues found that the government-levied charges on a Toronto to Montreal flight alone ($68) were enough to pay for a budget flight from Los Angeles to Las Vegas. This isn't the first time that Ottawa's ownership of airport lands has been tied to higher ticket prices. A Senate committee recommended in 2013 that Transport Canada make a plan to phase out rental fees and transfer ownership of airports to the airport authorities that operate them. 'Many witnesses raised concerns that these rents do not take into account the differing state and value of airport facilities when they were first transferred to the airport authorities … Since the airport authorities are mandated to be not-for-profit entities, witnesses told the committee that these costs are recovered from users,' wrote committee members. This recommendation was never followed up on, despite the subsequent spike in rent costs. A spokesperson for Transport Minister Chrystia Freeland declined to say if she intends to start the process of divesting government ownership of major airports. Polls show that Canadians are largely dissatisfied with the quality and selection of domestic air travel. A recent Leger/National Post study found that half of Canadians are open to allowing U.S.-owned airlines to fly domestic passenger routes in Canada. National Post rmohamed@ Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.
